D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide

D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide is an experimental small molecule dipeptide, classified as an alpha-dipeptide and amidine derivative. It has been studied primarily as a prothrombin inhibitor, suggesting anticoagulant potential. There are no approved indications or marketed formulations for this compound, and it has not advanced beyond preclinical or early experimental stages. Its mechanism of action involves inhibition of the coagulation protein prothrombin[1][2][4]. Additionally, computational drug design studies have considered it as a candidate for targeting liver-stage malaria by inhibiting essential *Plasmodium* enzymes[8].

Other names

D-Leucyl-N-(4-Carbamimidoylbenzyl)-L-Prolinamide(2S)-1-[(2R)-2-amino-4-methylpentanoyl]-N-[(4-carbamimidoylphenyl)methyl]pyrrolidine-2-carboxamide(2S)-1-((2R)-2-amino-4-methylpentanoyl)-N-((4-carbamimidoylphenyl)methyl)pyrrolidine-2-carboxamide